Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
February 15 2022 - 8:25AM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or
“PAVmed”), a diversified commercial-stage medical technology
company and parent of cancer prevention company Lucid
Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today
announced the appointment of prominent healthcare services industry
leader and president of Care Solutions for Evernorth, Joan Harvey,
to its Board of Directors. Ms. Harvey will serve as a member of the
Company’s Audit and Compensation Committees.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220215005417/en/
PAVmed appoints Joan Harvey to its Board
of Directors. (Photo: Business Wire)
“Ms. Harvey brings a wealth of health care experience, strong
track record in strategic and business development, and deep
financial acumen to our board,” said Lishan Aklog M.D., PAVmed’s
chairman and chief executive officer. “She shares our passion for
applying innovative technologies and care models to improve health
outcomes, and her contributions will be invaluable as we drive
commercial growth, expand our clinical services—including our
network of diagnostic test centers—and partner with payors.”
“PAVmed’s groundbreaking health technologies combined with their
strong clinical and research teams have tremendous potential to
propel the health care industry forward,” said Ms. Harvey. “Their
products have the ability to transform how we prevent, diagnose,
and treat some of the most complex and debilitating diseases. I
look forward to contributing to PAVmed’s ongoing success and
transformation into a leading global medical technology
company.”
Ms. Harvey has more than two decades of health care experience
serving in a variety of leadership roles dedicated to improving
whole person health and advocating for patients. She is the
president of Care Solutions for Evernorth, Cigna Corporation’s
(NYSE: CI) health services business. In this role, she oversees
Evernorth’s medical, behavioral, and pharmacy clinical programs to
meet the diverse needs of health plans, employers, government
organizations—and the people they serve.
Prior to joining Evernorth, Ms. Harvey served in senior
leadership roles at Cigna, Medco Health Solutions Inc., WellPoint
360 Health. a subsidiary of Anthem, Inc., American Imaging
Management, and Oxford Health Plans, LLC, a subsidiary of
UnitedHealth Group. She is a founding member of the Disease
Management Association of America, and author of “Asthma Disease
Management in the 21st Century” for the Managed Care Handbook: Best
Practices in Medical Management. Ms. Harvey holds a Master of
Business Administration from the American Graduate School of
International Management and a Bachelor’s degree in International
Relations from Bates College.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Another major
subsidiary, Veris Health Inc., is a digital health company
developing the first intelligent implantable vascular access port
with biologic sensors and wireless communication to improve
personalized cancer care through remote patient monitoring.
PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome is currently in limited commercial release. The product
pipeline also includes the EsoCure™ Esophageal Ablation Device with
Caldus™ Technology, which complements EsoGuard and EsoCheck, the
NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable
Intraosseous Vascular Access Device, novel pediatric ear tubes,
mechanical circulatory support technology and glucose monitoring.
For more information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock; PAVmed’s Series W and Series Z
warrants; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time
required to advance PAVmed’s products to regulatory submission;
whether regulatory authorities will be satisfied with the design of
and results from PAVmed’s clinical and preclinical studies; whether
and when PAVmed’s products are cleared by regulatory authorities;
market acceptance of PAVmed’s and products once cleared and
commercialized; PAVmed’s ability to raise additional funding as
needed; and other competitive developments. In addition, PAVmed has
been monitoring the COVID-19 pandemic and the pandemic’s impact on
PAVmed’s businesses. PAVmed expects the significance of the
COVID-19 pandemic, including the extent of its effect on its
financial and operational results, to be dictated by, among other
things, the success of efforts to contain the pandemic and the
impact of such efforts on PAVmed’s businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond PAVmed’s control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect PAVmed’s future operations, see Part
I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report
on Form 10-K filed with the Securities and Exchange Commission, as
the same may be updated in Part II, Item 1A, “Risk Factors” in any
Quarterly Report on Form 10-Q filed by PAVmed after its most recent
Annual Report filed with the Securities and Exchange Commission.
PAVmed disclaims any intention or obligation to publicly update or
revise any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220215005417/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com
Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024